Compare DexCom, Inc. (DXCM) vs MiniMed Group Inc. Common Stock (MMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MiniMed Group Inc. Common Stock — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while MiniMed Group Inc. Common Stock trades at $19.71 (market cap $5.57B). The key difference: DexCom, Inc. is far larger — about 5.7× MiniMed Group Inc. Common Stock's market cap, and MiniMed Group Inc. Common Stock is more actively traded (23,336,073 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and MiniMed Group Inc. Common Stock for 1 Days on average.
| DXCM | MMED | |
|---|---|---|
Market Cap | $31.86B | $5.57B |
Volume | 3,607,070 | 23,336,073 |
Sector | Health | Health |
52-Week High | $92.34 | $23.84 |
52-Week Low | $54.84 | $10.80 |
Typical Hold Time | 62 Days | 1 Days |
Enterprise Value | $31.32B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MiniMed Group Inc. Common Stock
MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →
